- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Shilpa Medicare Limited — Updates, 06-02-2026: General Updates
06-02-2026 | 02:50 pm
06-02-2026 | 02:50 pm
Shilpa Medicare reported strong Q3 results: revenue +28% YoY to 411 Cr, EBITDA +40% to 115 Cr. The company launched India's first-in-class NAFLD therapy, Noduca, and secured EU approval for Rotigotine. API and Biologics also showed good traction.
No comments yet. Be the first to comment!